ZESTORETIC Drug Patent Profile

When do Zestoretic patents expire, and what generic alternatives are available?

Zestoretic is a drug marketed by Almatica and is included in one NDA.

The generic ingredient in ZESTORETIC is hydrochlorothiazide; lisinopril. There are thirty-two drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; lisinopril profile page.

Summary for ZESTORETIC

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ZESTORETIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-003	Nov 18, 1993	AB	RX	Yes	No
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-001	Sep 20, 1990	AB	RX	Yes	No
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-002	Jul 20, 1989	AB	RX	Yes	No

International Patents for ZESTORETIC

See the table below for patents covering ZESTORETIC around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H032878
Bulgaria	38787	METHOD FOR PREPARING CARBOXYALKYL DIPEPTIDES
Ireland	48922	CARBOXYALKYL DIPEPTIDE DERIVATIVES,PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
Finland	793799
South Korea	840005083
Norway	794010
Spain	494300

Supplementary Protection Certificates for ZESTORETIC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454511	99C0009	Belgium		PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
0454511	SPC/GB99/008	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
0502314	SPC/GB02/037	United Kingdom		PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
0502314	C300095	Netherlands		PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
0480717	98C0025	Belgium		PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
0503785	CA 2011 00026	Denmark		PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
0443983	C00443983/03	Switzerland		PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009

ZESTORETIC: Investment Scenario and Fundamentals Analysis (Patent, Value Chain, and Competitive Risk)

Last updated: April 23, 2026

What is ZESTORETIC and where does it sit in the market?

Zestoretic is a fixed-dose antihypertensive combination of an ACE inhibitor plus a thiazide diuretic: lisinopril + hydrochlorothiazide (HCTZ). It is used for hypertension and is typically positioned as a once-daily, cost-effective regimen versus monotherapy followed by add-on therapy.

What is the core revenue driver: dosing, substitution, and payer economics?

The revenue model for ACE inhibitor plus thiazide fixed-dose products is dominated by:

• Formulary placement (preferred vs non-preferred tiers) and step therapy rules
• Low-cost generic erosion after first patent expiries
• Switching behavior tied to pill burden and tolerability rather than brand differentiation

Given that Zestoretic is a long-established product, the investment case is shaped less by clinical differentiation and more by:

• The durability of label-constrained use and tolerability positioning
• The strength of generic competitors and authorized generics
• Ongoing channel economics in large markets where HCTZ-based combinations face heavy price competition

How does patent reality frame the investment case?

For established ACE inhibitor + thiazide fixed-dose brands, the dominant patent question is not whether the combination is protected, but whether any secondary protections (formulations, fixed-dose ratios, polymorphs, manufacturing processes, or method-of-use claims) survive in major markets.

For Zestoretic specifically, the available patent landscape is best characterized as a product category with:

• Early composition coverage long expired for most geographies
• Limited remaining scope likely to be formulation- or manufacturing-related
• High likelihood that the brand is already competing against multiple generics

Investment implication: the fundamentals align with a mature, low-margin-to-average economics profile typical for fixed-dose antihypertensive combinations unless a company controls a protected niche or supply advantage.

What does the evidence base suggest about market durability?

ACE inhibitor + thiazide combinations have entrenched guideline status for hypertension. The clinical practice pattern supports:

• sustained patient demand for low-cost effective regimens
• high substitutability among equivalent ACEi and thiazide combinations
• rapid generic uptake when patents expire

That combination class has also benefited from decades of prescribing familiarity, which tends to stabilize volumes even as pricing declines.

Which competitors matter most: direct AB-rated substitution and class switching?

Zestoretic faces competition on two layers:

1) Direct fixed-dose AB substitution
Patients can switch to any lisinopril/HCTZ fixed-dose generic or authorized-generic equivalent.

2) Class-level switching within hypertension
Clinicians and payers can substitute:

• ACE inhibitor + thiazide combinations from other ACE inhibitors plus HCTZ
• ACE inhibitor + thiazide fixed-dose products in alternative ratios
• ARB + thiazide combinations when tolerability, cost, or guideline preference drives selection

Investment implication: absent meaningful patent exclusivity or differentiated dosing convenience protected by law, competitive intensity usually results in compressed brand pricing.

How is the product regulated and labeled in ways that affect revenue?

Zestoretic is an FDA-approved drug product with a specific labeling profile for:

• dosing and titration
• contraindications (notably pregnancy)
• monitoring requirements (renal function and electrolytes)
• safety warnings (ACE inhibitor class risks)

In mature antihypertensive markets, labeling rarely constrains generic substitution because generics must meet bioequivalence standards and present the same active ingredients and route of administration.

Investment implication: regulatory equivalence accelerates generic replacement, limiting the upside from brand-style retention unless a firm holds manufacturing or regulatory exclusivity that outlasts typical patent timelines.

What does the regulatory ecosystem imply for growth prospects?

In hypertension, volume growth is limited by:

• the size of treated populations
• switching behavior among low-cost options
• payer formulary stability favoring lowest-cost equivalents

So the investment thesis rests on operational and commercial execution:

• maintaining supply reliability
• defending contract manufacturing volumes
• leveraging distribution relationships and pharmacy benefit manager (PBM) positioning

How should an investor model cash flows for Zestoretic?

A practical model for a mature fixed-dose ACEi/HCTZ brand should treat the equity story as commercial execution plus margin discipline, not innovation-led re-rating.

Key model lines:

• Net sales durability: assume erosion tied to generic penetration
• Gross margin: assume continued downward trend unless branded channel share is defended by payer mix or specialty contracting
• SG&A efficiency: track whether spend scales down in line with volume
• Manufacturing economics: track cost of goods and any supply constraints that could temporarily raise or protect pricing
• Legal and exclusivity events: treat patent/litigation outcomes as episodic variance

What are the patent and litigation risk contours for this category?

The primary risks for Zestoretic-type products are:

• generic launches at scale immediately after relevant exclusivities expire
• settlement agreements that delay but do not eliminate erosion
• process or formulation patents that may or may not be enforceable depending on jurisdiction

Because fixed-dose antihypertensive combinations are well established, the probability-weighted outcome typically trends toward:

• continued generic commoditization
• pressure on brand unit economics
• a value chain shift toward whoever controls low-cost supply and channel access

Investment scenario: base case, downside, and upside

Base case

• Ongoing conversion to generics reduces brand share over time
• pricing continues to track PBM and wholesaler benchmarks
• earnings reflect stable demand but declining brand economics

Downside

• faster-than-expected market share loss from new generic entrants or aggressive PBM contract shifts
• margin compression from cost inflation in manufacturing inputs or intensified distributor rebates
• increased headcount or legal spend without a matching revenue defense

Upside

• a temporary re-acceleration if a specific strength or dosing regimen achieves longer formulary retention
• channel-specific contract renewal that protects higher net-to-gross rates
• successful defense of narrow legal positions that delay full erosion in one or more markets

What fundamentals matter most for valuation?

For investors evaluating Zestoretic exposure (brand owner, contract seller, or supply-chain participant), the decision hinges on:

• Net price realization vs generic benchmarks (especially in major payer networks)
• Gross margin stability despite generic pressure
• share of channel where fixed-dose combination retention remains durable
• manufacturing capacity and cost position relative to generic competitors
• litigation calendar and any remaining exclusivity that can extend periods of pricing power

Where is the value chain strongest: manufacturing, distribution, or brand ownership?

In mature antihypertensive combinations:

• Manufacturing advantage (scale, yield, and input sourcing) usually creates the most durable economic edge.
• Distribution and PBM contracting determine the realized price more than premium clinical attributes.
• Brand ownership value tends to shrink as generic penetration rises unless the brand remains non-substitutable in a meaningful segment (rare for AB-rated products).

Key takeaways on the investment posture

• Zestoretic is a mature fixed-dose antihypertensive (lisinopril + hydrochlorothiazide).
• Fundamentals are governed by generic substitution, PBM contracting, and supply-cost discipline, not by late-stage innovation.
• The risk profile is typical of established cardiovascular generics: price erosion is the default outcome.
• Returns depend on whether the investor’s exposure is anchored to cost position, channel contracts, and the ability to manage margin under commoditization.

---

Key Takeaways

• Zestoretic is an ACE inhibitor + thiazide fixed-dose hypertension product (lisinopril/HCTZ), operating in a commoditized category.
• The investment case is primarily about net price realization, gross margin, manufacturing economics, and formulary access, not patented differentiation.
• Competitive risk is high due to direct fixed-dose generic substitution and class-level switching across antihypertensives.
• Scenario analysis should assume continued erosion; upside comes from niche channel retention, supply advantage, or legal timing that delays full replacement.

---

FAQs

1) Is Zestoretic still a branded product with meaningful exclusivity?
Zestoretic is a long-established fixed-dose combination; economics typically reflect post-exclusivity conditions with heavy generic substitution.

2) What drives revenue most for Zestoretic?
PBM formulary placement, step-therapy rules, and relative pricing versus AB-rated lisinopril/HCTZ generics.

3) How quickly does generic competition usually affect this category?
Fixed-dose hypertension combinations commonly experience rapid market share erosion after relevant exclusivities end.

4) What are the main competitive threats beyond direct generics?
ACEi/HCTZ competitors using other ACE inhibitors plus HCTZ and ARB/HCTZ fixed-dose alternatives.

5) What operational factors protect profitability in a mature market?
Low-cost manufacturing scale, rebate and contract management, and stable supply that prevents lost formulary share.

---

References

[1] FDA. Zestoretic (lisinopril and hydrochlorothiazide) prescribing information (accessed via FDA labeling repository).
[2] FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (lisinopril and hydrochlorothiazide fixed-dose listings).
[3] ACC/AHA. 2017 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (hypertension pharmacotherapy recommendations).